ALS Untangled No.33 Endotherapia

Figures & data

Figure 1. An example of the antibody pattern being used by proponents of Endotherapia to treat a patient with ALS (5).

Legend reads (translated from French): ‘Indirect ELISA technique was used. The ‘immunobilan’ is a biological test that quantifies the number of circulating antibodies in the serum of patients affected with chronic conditions (based on draw of 5 ml of serum)’.

Interpretation:

- Values greater than or equal to +2 indicate elevated levels of circulating antibodies.

- Values less than or equal to –2 indicate the formation of immune-complexes

Immune System Activation:

- M = IgM

- A = IgA

- G = IgG

Composition of ‘Type B Bilan’

- Indicators of hyperproduction of tryptophan and hyperproduction of NO and NO₂ (free radical involvement).

- Indicators of mucosal hyperpermeability = IgA.

- Indicators of mucosal dysbiosis = IgA.

- Indicators of mycobacterial activation = IgG and IgA.

Indications of ‘Type B Bilan’:

Parkinsons, Alzheimer’s, MS, ALS, spinocerebellar ataxia, Huntington’s, macrophage-induced ‘myofasciite’, progressive supranuclear palsy, multi-system atrophy, Alexander’s disease, Alpers disease, Creutzfeldt-Jakob, Pick’s disease, lysosomal disorder.

Graph 1: Activation of immune system following activation of ‘IDO’ pathways and NO synthases.

Graph 2: Activation of immune system by bacterial constituents, following mucosal hyperpermeability.

Graph 3: Activation or re-activation of immune system after dysbiosis.

Graph 4: Activation or re-activation of immune system by bacterial constituents linked to mycobacteria.

Table I. Components of the Endotherapia cocktail for patients with ALS (4).

Fatty acids, sterols and derivatives	Anti-oxidants and scavengers	Amino acids and derivatives
Oleic-PLL-Thioctic	Pantothenic-PLL	Uric Acid-F-PLL
Oleic-PLL-Palmitolec	Oleic-PLL-Retinoic	Taurine-GA-PLL
Oleic-PLL-Palmitic	Oleic-PLL-Coenzyme Q10	L-Methionine-GA-PLL
Oleic-PLL-Myristic	Biotin-PLL	Glucosamine-GA-PLL
Oleic-PLL-Linoleic	Ascorbic Acid-PLL	L-Cysteine-GA-PLL
Oleic-PLL-Lauric	Alpha Tocopherol-PLL	Taurine-G-PLL
Lauric-PLL-Caprylic		L-Methionine-G-PLL
FarCys-PLL-Palmitic		L-Glutathione-G-PLL
Cholesterol-PLL-Oleic		L-Cysteine-G-PLLAgmatine-G-PLL

Table II. TOE Grades for Endotherapia as an ALS treatment.

	Grade	Explanation
Mechanism	D	Endotherapia may act on a biological mechanism, but it is not clear this mechanism is relevant in ALS
Pre-clinical	C	One flawed publication reports benefit in an ALS rat model
Cases	D	Subjective report of benefit without independently validated diagnosis or benefits
Trials	D	One or more published reports of benefit in a flawed trial
Risks	U	There has been no clear systematic safety monitoring of PALS on Endotherapia

http://www.idrpht.info/Immuno-Bilan#/Immuno-Bilan/. Accessed December 3, 2015.

 Google Scholar

Geffard M, DeBisschop L, Duleu S, Hassaine N, Mangas A, Covenas R. Endotherapia: a new frontier in the treatment of multiple sclerosis and other chronic diseases. Discovery Medicine. 2010;10:443–51.

 PubMed Web of Science ®Google Scholar